{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-084468","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.427700+00:00","generated_at":"2026-06-13T00:50:02.052821+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia submits NDA amendment to add PH-ILD indication for YUTREPIA; no new clinical data","bullets":["Submitted amendment to add PH-ILD indication to tentatively approved NDA for YUTREPIA; no new clinical data needed.","Final approval of PH-ILD indication possible after Tyvaso exclusivity expires March 31, 2024.","Recertified paragraph IV that YUTREPIA does not infringe Tyvaso patents; all prior patent challenges won.","Preparing for potential YUTREPIA launch between end of 2023 and mid-2024.","Third Amendment to HCR financing: $10M second tranche received; future tranches require mutual agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-084468","json":"https://secwatch.observer/filing/0001104659-23-084468.json","markdown":"https://secwatch.observer/filing/0001104659-23-084468.md","text":"https://secwatch.observer/filing/0001104659-23-084468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/0001104659-23-084468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/tm2322220d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:50:02.052821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7120ef4f372a87a6e69f8d671419b02b6077102","claim":"Liquidia Corp amended Third Amendment to the Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC (collectively, “HCR”) valued at $10 million second tranche (effective 2023-07-27).","evidence_excerpt":"On July 27, 2023, Liquidia Technologies and HCR entered into a Third Amendment to the Financing Agreement (the “Third Amendment”), pursuant to which, among other things, (i) HCR agreed to make payment of the $10 million second tranche under the Financing Agreement on July 27, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/0001104659-23-084468-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC (collectively, “HCR”)"},{"label":"Value","value":"$10 million second tranche"},{"label":"Effective","value":"2023-07-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}